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1. Introduction
In November 1999, an ‘Inside Track’ Conference of
the European School of Oncology (ESO) on the ‘Biolo-
gical Basis for Antiangiogenic Therapy’ was held in
Milan, Italy. This conference provided an opportunity
to discuss the biological rationale for dierent anti-
angiogenic therapies, along with the optimisation of
clinical trial designs using single or multiple agents and
the analysis of the outcomes and future directions. The
conference was timely, with a booming interest in
angiogenesis as a therapeutic target and its clinical
trials, in particular with endostatin, recently occurring.
Approximately 400 participants, both basic scientists
and clinicians attended the conference, a fact that
demonstrates the wide interest raised by the basic
research on the angiogenic process and its clinical
applications. More than 100 abstracts were submitted to
the conference for poster/oral presentation [1], providing
a stimulating ground for discussion and a network of
interactive collaboration between scientists and clinicians.
This report briefly summarises the topics discussed at
the conference focusing on the newest findings and
controversial issues presented by the faculty members.
2. The process of angiogenesis
Angiogenesis, the formation of new blood vessels
from pre-existing ones, and the permeability of blood
vessels are regulated by a family of vascular endothelial
growth factors and receptors. One concept that emerged
during the conference is that at least two of these factors
are also involved in lymphangiogenesis [2]. Vascular
endothelial growth factor receptor (VEGFR)-3 and its
ligand, VEGF-C, are involved in embryo mouse devel-
opment and in some models of angiogenesis in adult
life. VEGFR-3ÿ/ÿ mouse embryos died after 10.5 days
of gestation with alterations in the pericardium and
vascular remodelling, while VEGFR-3+/ÿ mice did not
show any defects. In early embryonic life, this receptor
is expressed on vascular endothelial cells, but it is then
downregulated and appears in lymphatic vessels. In
adult life, it is exclusively present on lymphatic vessels in
mice as well as in humans. However, it is transcribed in
vivo in proliferating endothelial cells at the sites of
angiogenesis (e.g. angiogenesis in breast cancer).
Mutations in its kinase domain were found in patients
aected by autosomal dominant hereditary lymph-
oedema. VEGF-C has been defined as the ligand of
VEGFR-3. However, VEGF-C can also bind VEGFR-2
and trigger vascular endothelial cell activation in adults
as well. By using the mutant VEGF-C 156S, which does
not bind VEGFR-2, it was established that VEGFR-3 is
involved in cell migration and sprouting. In onco-
genesis, VEGF-C seems to play an important role in
lymphatic metastasis. Indeed, Rip-1–Tag-2 transgenic
mice develop pancreatic insulinomas, which do not
metastasise, whereas the tumours spread by lymphatic
metastases in Rip-1–Tag-2/Rip-1–VEGF-C transgenic
mice.
Hypoxia plays a complex role in tumour growth act-
ing as an on switch for inducible tumour angiogenesis
factors.VEGF-A gene transcription is actually upregulated
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by hypoxia [3]. Low pO2 (partial oxygen pressure) acts
on VEGF-A mRNA levels by increasing the rate of
synthesis and stabilisation of the transcript and, at the
translational level, through a hypoxic-refractory inter-
nal ribosome entry site (IRES). During development,
the pO2 controls the formation of the vasculature by
influencing VEGF-A levels: hypoxia upregulates the
hypoxia-inducible factor (HIF)-1a, which binds to the
VEGF-A promoter, starting its transcription. In fact, in
HIF-1aÿ/ÿ mice, hypoxia, as well as hypoglycaemia, do
not upregulate VEGF-A expression. In immature ves-
sels, hyperoxia downregulates VEGF-A expression and
promotes vascular regression. However, when vessel
formation is completed and pericytes have been recrui-
ted, capillaries are no longer sensitive to the survival
eect of VEGF-A and hyperoxia does not induce their
regression. This is well demonstrated in the human
glioblastoma model, where vessels lacking pericytes are
strictly dependent on VEGF-A.
In fact, hypoxia activates the transcription of a family
of hypoxia-inducible factors, specifically HIF-1a and
HIF-2a [4]. These factors have a dierent role according
to the genetic background of the cell population, as
shown by the observation that under hypoxic condi-
tions, the apoptotic and death rate of normal cells
decreases if HIF-1a is knocked-out, while for tumour
cells the rate of apoptosis increases. Clearly, the expres-
sion of HIFs could be considered as a biological marker
of tumour behaviour, and the hypoxia signalling path-
way is now proposed as a therapeutic target for gene
therapy.
The angiopoietins (Ang) have recently joined the
VEGFs as the only known growth factor families that
are highly specific for the vascular endothelium. VEGFs
and Ang work together in a complementary and coor-
dinated manner in all aspects of vascular biology [5].
Four angiopoietin molecules have been cloned. Ang-1
and -4 activate the kinase activity of their receptor, Tie-
2. Ang-2 and -3 are natural antagonists of this receptor.
Ang-1 is a survival molecule for endothelial cells and in
Ang-1ÿ/ÿ mice there is a defect in capillary network
maturation, characterised by a lack of contact between
endothelial cells and pericytes. In the embryo, Ang-1 is
instrumental for vessel maturation by recruiting peri-
cytes and probably smooth muscle cells. In stabilised
adult vessels, Ang-1 appears to constitutively engage its
receptor, and therefore probably does not play a role in
vessel maintenance. In this case, Ang-2 destabilises the
interaction between the endothelium and pericytes and
renders endothelial cells responsive to VEGF-A trigger-
ing of angiogenesis. In the absence of VEGF-A, vessels
disappear. The co-optation mechanism of angiogenesis,
characterised by the tumour growth around pre-existing
vessels, seems to be operative in the C6 glioblastoma
model. The presence of Ang-2 and the absence of
VEGF-A induces necrosis of the central area of the
tumour. The tumour cells then release angiogenic mol-
ecules, which induce neoangiogenesis from the sur-
rounding capillaries.
3. Targeting angiogenic factors
Inducers and inhibitors of angiogenesis are candidates
for modulation during tumour development and are a
potential target for therapeutic intervention. In a study
by Ferrara and colleagues, the importance of VEGF in
new blood vessel formation and survival was again
emphasised [6]. VEGF expression is a requirement for
growth and survival in neonatal mice. Two independent
approaches were used to inactivate the VEGF protein in
newborn mice: (1) inducible, Cre–loxP-mediated gene
targeting; or (2) administration of mFlt(1-3)–IgG, a
soluble VEGF receptor chimeric protein. Partial inhibi-
tion of VEGF achieved by inducible gene targeting
resulted in increased mortality, stunted body growth
and impaired organ development, most notably of the
liver. Administration of mFlt(1-3)–IgG, which achieves
a higher degree of VEGF inhibition, resulted in nearly
complete growth arrest and lethality with signs of liver
and renal failure. Endothelial cells isolated from the
liver of mFlt(1-3)–IgG-treated neonates demonstrated
an increased apoptotic index, indicating that VEGF is
required not only for proliferation, but also for the sur-
vival of endothelial cells. Administration of mFlt(1-3)–
IgG to juvenile mice instead failed to induce apoptosis
in liver endothelial cells. Thus, VEGF is essential for the
growth and survival in early postnatal life, but VEGF
dependence is eventually lost some time after the fourth
postnatal week. In the fully developed animal, VEGF is
likely to be primarily involved in active angiogenesis
processes such as corpus luteum development, as shown
by the capacity of mFlt(1-3)–IgG to inhibit hormonally-
induced ovulation in female rats. Furthermore, systemic
administration of Flt-(1-3)–IgG to 24-day-old mice
revealed a role for VEGF in hypertrophic cartilage
remodelling, ossification and angiogenesis during endo-
chondral bone formation. These observations raise the
question of the possible biological consequences of
therapeutic administration of VEGF/VEGF-receptor
antagonists on physiological angiogenesis. Valuable
information on these aspects will be obtained from the
results of the ongoing clinical trials with humanised
anti-VEGF antibody in prostate, lung and breast
tumour patients.
Development of low molecular weight compounds
able to inhibit VEGF receptor-mediated signalling
appears to be a fruitful approach for the discovery of
potent antiangiogenic compounds. Inhibitors of VEGF
receptor tyrosine kinase(s) are already under investiga-
tion in clinical trials. The tyrosine kinase (TK) inhibi-
tors SU5416 and SU6668 have entered phase II/III and
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phase I clinical trials, respectively [7]. Both molecules
act as adenosine triphosphate (ATP) competitive inhi-
bitors for the TK domain of growth factor receptors.
SU5416 shows a certain specificity for the VEGF
receptor Flk-1/KDR and SU6668 is a potent inhibitor
of VEGF, fibroblast growth factor (FGF) and platelet-
derived growth factor (PDGF) receptors. SU5416 and
SU6668 inhibit the growth of various human tumour
cell lines implanted in nude mice, decreasing the number
of metastases and increasing animal survival. Interest-
ingly, SU6668 was able to cause tumour regression in
lung A431 and colon Colo205 carcinoma xenografts,
even when treatment was started in animals with a large
tumour burden. These data, together with its oral
availability and low toxicity, point to SU6668 as a
potentially interesting candidate for anti-angiogenesis
therapy.
The possibility to inhibit angiogenesis and experi-
mental tumour growth by using selective TK inhibitors
is supported by the results obtained with ZD4190 [8].
ZD4190 is a potent and selective inhibitor of the TK
activity of VEGF receptors, Flt-1 and KDR. In vivo,
ZD4190 inhibits VEGF-induced acute hypotension and
causes epiphyseal hypertrophy in growing rat femurs by
inhibiting bone angiogenesis. In addition, it inhibits
tumour growth when tested on a panel of tumour
xenografts. However, tumour growth resumed at a nor-
mal rate when therapy was interrupted.
The results of ongoing clinical trials with humanised
anti-VEGF antibody and low molecular weight TK-
VEGF receptor inhibitors are eagerly awaited.
4. Targeting endothelial cell functions
Genetic and biochemical pathways govern the assem-
bly and disassembly of the vasculature during tumour
growth, thus endothelial cell functions have become
targets for anti-angiogenic approaches. The signalling
and cross-talk among vascular cells are governed by a
family of interendothelial junctions. The adhesion
molecule vascular endothelial (VE)-cadherin homo-
typically links endothelial cells and is instrumental not
only in the proper assembly of vascular structures dur-
ing the remodelling and maturation of the vasculature,
but it could be an exciting new template for the devel-
opment of new anti-angiogenic drugs [9].
The importance of the biochemical machinery of
endothelial cells in the control of the balance between
degradation and matrix re-assembly of the vascular
network during angiogenesis has been demonstrated by
the ecacy of the matrix metalloprotease inhibitors
(MMPIs) in blocking endothelial and tumour cell inva-
sion, and ultimately angiogenesis. Human ovarian car-
cinomas (HOC) produce high levels of MMP-2 and
MMP-9 that correlate with tumour progression. Bati-
mastat (BB-94), used as a standard agent, aects
tumour growth and spread in the HOC xenograft
model. However, as is expected for this type of cyto-
static-like therapy, tumour inhibition is only partial.
Treatment with MMPIs in combination with cytotoxic
therapy (i.e. cisplatin) increased the antitumour eects,
while prolonged treatment with MMPIs maintained the
response to cytotoxic therapy [10]. This finding opens
the issue of using a combination of antiangiogenic
compounds with conventional therapies.
A critical issue in cancer therapy is the avoidance of
acquired tumour cell drug resistance by the targeting of
endothelial cells. A link exists among the oncogenes
aecting tumour growth via the induction or upregula-
tion of angiogenic factors [11]. Many drugs developed
to block the signal transduction cascades triggered by
oncogenes may also function ‘accidentally’ as anti-
angiogenic compounds in experimental tumours.
The use of standard chemotherapies administered at
low, frequent doses was also broadly discussed at the
meeting. Special interest was raised by the fact that such
a strategy could control tumour growth of drug-resis-
tant tumours by acting on the tumour vasculature.
5. Targeting the vascular endothelium
Vascular targeting is an innovative way to develop
treatment strategies that rely on their eect on the
already formed vasculature that could lead to advances
in cancer treatment. By an in vivo selection, phages
selectively homing to dierent tissues are recovered
from a phage display peptide library following intrave-
nous administration in mice [12]. Using this strategy,
several organ- and tumour-homing peptides were iso-
lated. These peptides bound to dierent receptors selec-
tively expressed on the vascular cells of the target tissue.
The tumour-homing peptides bound to receptors that
are upregulated in the vasculature of angiogenic
tumours. Taking advantage of this, these peptides could
be used to deliver cytotoxic drugs to the tumour vessels.
Successful delivery of doxorubicin demonstrated the
proof-of-principle for this approach. It is clear that this
technology could be extended to targeting various drugs
and radioisotopes to tumours, potentially reducing the
systemic damage that occurs following radio- or
chemotherapy. R. Pasqualini also described the isola-
tion of a specific gelatinase (type IV collagenase) inhi-
bitor from phage display peptide libraries. The sequence
HWGF is present in potent and selective inhibitors of
MMP-2 and MMP-9 that do not inhibit other MMP
family members. Synthetic peptides containing the
sequence HWGF (the angiogenic ‘zip code’) inhibit the
migration of endothelial and tumour cells in vitro and
prevent tumour growth in vivo. Molecular diversity of
the vascular beds was therefore proven by the targeting
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of various tissues by means of dierent peptide motifs.
Organ- and tissue-specific heterogeneity of the vascu-
lature could serve as a selective molecular ‘address’ for
therapy.
There are promising compounds that selectively target
tumour vasculature currently under development for
cancer treatment. The tubulin-binding agent com-
bretastatin A-4 phosphate is selectively toxic for pro-
liferating endothelial cells in vitro and acts on tumours
in vivo by inducing vascular shutdown [13]. The selective
cytotoxic eect on proliferating endothelial cells of
combretastatin A-4 seems to be mediated by apoptosis
rather than by necrosis. The strong antitumour eects
obtained by combretastatin A-4 were associated with
the irreversible reduction of tumour blood flow and
impairment of the nutritional supply into the tumour
tissue. This agent has recently entered phase I clinical
trials as a vascular targeting agent.
The selective occlusion of the tumour vasculature by
the formation of blood clots (thrombosis) within the
tumour vessels is another successful way to target
tumour vasculature [14]. This result was achieved by
targeting clotting agents to the cell surface domain of
human tissue factor, by means of a bispecific antibody.
Another example of targeting the endothelial cells of the
tumour vasculature, rather than the tumour cells them-
selves, is the use of an antibody against endoglin, an
endothelial cell proliferation marker upregulated on
tumour endothelial cells. The anti-endoglin antibody
might have therapeutic value by selectively killing the
dividing endothelial cells that are prevalent in tumours.
Other potential candidate molecules for targeting are
the adhesion molecules vascular cell adhesion molecule
(VCAM)-1, and E-selectin, the avb3 integrin, and the
VEGF-receptor complex.
6. Clinical applications
The prognostic relevance of the histopathological
microvessel count and the clinical value of the surrogate
markers of angiogenesis were the object of controversial
discussions. A comprehensive lecture on the clinical
significance of the determination of angiogenesis in
breast cancer [15], reported that, in the 36 retrospective
studies analysed in the literature, the microvessel count
in the tumour ‘hot spot’ have convincingly demon-
strated the existence of a strong correlation of this
marker to prognosis. Nevertheless, the critical issue of a
lack of international standardisation for the methodol-
ogy is still a strong limitation to its use on a routine
basis for all types of cancer. In this scenario, the mea-
sure of angiogenesis parameters and their correlation
with progression and response to treatment appears to
be a very promising approach to be adopted for breast
cancer at the clinical level.
The hypothesis has been explored that resistance to
antiangiogenic treatment could be explained by the
existence of non-angiogenic tumours that take their
blood supply from pre-existing vessels of the surround-
ing tissue [16]. A dierent phenotype of the vessels pres-
ent in angiogenic and truly non-angiogenic primary
non-small cell lung cancer (NSCLC) was demonstrated,
as well as dierences in microvessel density (MVD)
among primary breast cancers and lymph node or lung
metastases from those tumours. By analysing the intra-
tumour vessel expression of avb3 (expressed on new
vessels), of LH39 (expressed on mature vessels) and of
cell determinant (CD)31, one can conclude that the
phenotype of the vessels present in putative non-angio-
genic NSCLC is that of the pre-existent mature vessels
and not the immature phenotype expected from a new
angiogenesis. Furthermore, statistically significant dif-
ferences in the MVD between primary breast cancers
and synchronous lung and or lymph node metastases
have been observed. The MVD in lung metastases was
always higher when compared either with their primary
tumour (angiogenic or non-angiogenic) or to the lymph
node tumours. This intriguing observation also supports
the hypothesis that angiogenesis might be influenced by
the site of metastases.
The angiogenic pathway is controlled by the local
balance between molecules that stimulate (FGF2,
VEGF, type IV collagenase, etc.) or inhibit this process
[17]. The modulation of these molecules represents the
first rational therapeutic approach to angiogenesis.
Transforming growth factor (TGF)a present in tumours
can induce hyperplasia that produces angiogenic mol-
ecules used by the tumour to expand. The interferons a
and b have a role in inhibiting angiogenesis through the
downregulation of the transcription and protein pro-
duction of FGF2, collagenase IV and the metallopro-
tease MMP-9. For example, the angiogenic growth of
haemangiomas and melanomas in the presence of FGF2
and VEGF was associated with a local deficiency of
interferon (IFN) that, on the contrary, was present
nearby in the normal tissue. Furthermore, 78% of
human carcinomas have a deletion of the short arm of
chromosome 9 where the IFN gene is located. The use
of IFNs as antiangiogenic agents is intriguing because
there is no direct dose–eect relationship, i.e. a higher
dose did not produce better results and the administra-
tion schedule was very important. This was clearly
demonstrated in an experimental model using IFN-a
against human bladder cancer cells (resistant to the
antiproliferative eect of IFNs) implanted in the blad-
der of nude mice: daily low doses of IFN-a were active
in inhibiting FGF2 andMMP-9 expression and impaired
tumour growth.
Several novel proteins with antiangiogenic properties
have been discovered. Specifically, a new cryptic endo-
genous inhibitor of angiogenesis, a 53 kDa fragment of
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antithrombin III generated by proteolytic digestion by
an unknown protease [18] was reported. It inhibits the
proliferation of endothelial cells in vitro and the growth
of a neuroblastoma cell line in vivo. Its therapeutic e-
cacy was more that 95% and similar to that of endo-
statin and angiostatin. It is now known that angiostatin
and endostatin can be generated by proteolytic cleavage
of plasminogen by MMP-2, and of collagen XVIII by
elastase, respectively. These endogenous inhibitors are
normally released by primary tumours and they appear
to inhibit the growth of metastases. Actually, in animal
models (e.g. Lewis Lung carcinoma) and in humans,
removal of the primary lesion is often followed by rapid
formation of metastases. It is possible to hypothesise
that other endogenous angiogenic inhibitors could be
generated by larger molecules (for instance other zymo-
gens participating in the coagulation cascade). With
endostatin having just entered clinical trials, its ecacy
in controlling the growth of several human and murine
tumour cell lines highlighted problems concerning the
stability of the molecule. The central role of Zn2+ and
of pH for the activity of endostatin has been revisited.
Finally, J. Folkman showed encouraging results that
have been obtained with young patients aected by
haemangiomas and treated with IFNa. The treatment
with this cytokine induced the regression of the lesion
without any appearance of drug resistance, a common
feature of conventional therapies.
Several anti-angiogenic compounds have entered
clinical trials [19]. There are two classes of angiogenesis
inhibitors resulting from the preclinical model system.
One type can be defined as ‘angiotoxic’ because the
agents are cytotoxic, targeting angiogenic endothelial
cells to a greater extent than normal or tumour cells.
These agents include TNP-470, thalidomide, com-
bretastatins, colchicines, squalamine and some che-
motherapeutic agents. They might have their clinical
activity detected according to fairly standard approa-
ches, where tumour shrinkage is the basis for scoring a
tumour response. A second class of agents are those
having targets which are uniquely expressed by pro-
liferating or migrating endothelial cells. They include
anti-angiogenic factor antibodies (i.e. anti-VEGF),
metalloprotease inhibitors, compounds that regulate
genes leading to elaboration of pro-angiogenic factors,
or growth-regulatory protein fragments such as endo-
statin or angiostatin. This type of agent may not have
easily detectable eects on tumour behaviour in con-
ventional early clinical trials. An important issue is the
necessity to establish a proper methodology to detect
the evidence of drug eects and biological endpoints
directed at endothelial cells.
Certainly we need to understand much more about
the biology of tumour angiogenesis. By identifying the
key molecular targets of the angiogenesis process, selec-
tive antagonists can be developed. A growing number of
angiostatic agents showing promising antitumour eects
in preclinical models are now entering clinical studies.
Despite the increasing number of molecules with angio-
static properties, the design of optimal regimens in
combination with conventional therapy, as well as the
need for surrogate markers for the selection and the
optimisation of antitumour ecacy, appear to be the
critical problems to be solved in the near future.
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